Low-dose erythropoietin treatment is not associated with clinical benefits in severely anaemic Jehovah’s Witnesses: a plea for a change.

Show simple item record

dc.contributor.author Beliaev, AM en
dc.contributor.author Allen, SJ en
dc.contributor.author Milsom, P en
dc.contributor.author Nand, P en
dc.contributor.author Smith, WM en
dc.contributor.author Bergin, Colleen en
dc.date.accessioned 2018-10-31T22:13:02Z en
dc.date.issued 2016-11-15 en
dc.identifier.issn 1723-2007 en
dc.identifier.uri http://hdl.handle.net/2292/43708 en
dc.description.abstract Jehovah’s Witnesses who refuse blood transfusion have high mortality. Erythropoietin (EPO) has been used as an alternative to blood transfusion. The optimal dosing of EPO in anaemic Jehovah’s Witnesses is unknown. The aim of our study was to evaluate the clinical benefits of treatment with a low dose (<600 IU/kg/week) of epoietin beta (EPO-β).This was an observational study, retrospectively considering a 10-year period during which 3,529 adult Jehovah’s Witnesses with a total of 10,786 hospital admissions were identified from databases of four major public hospitals in New Zealand. Patients with severe symptomatic anaemia (haemoglobin <80 g/L) who were unable to tolerate physical activity were included in the study. Patients treated without EPO were assigned to the conventional therapy group and those treated with EPO to the EPO treatment group.Ninety-one Jehovah’s Witnesses met the eligibility criteria. Propensity score matching yielded a total of 57 patients. Patients treated with conventional therapy and those treated with EPO had similar durations of severe anaemia (average difference 6.25 days, 95% confidence interval [CI]: -3.77-16.27 days; p=0.221). The mortality rate among Jehovah’s Witnesses treated with conventional therapy was 4.68 per year (95% CI: 2.23-9.82), while that in those treated with EPO was 2.77 per year (95% CI: 0.89-8.60). Treatment with EPO was associated with a mortality ratio of 0.59 (95% CI: 0.1-2.6; p=0.236). Both groups of patients had similar in-hospital survival (p=0.703).Treatment with low-dose EPO-β was not associated with either shorter duration of severe anaemia or a reduction in mortality. en
dc.format.medium Print-Electronic en
dc.language eng en
dc.relation.ispartofseries Blood transfusion = Trasfusione del sangue en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Low-dose erythropoietin treatment is not associated with clinical benefits in severely anaemic Jehovah’s Witnesses: a plea for a change. en
dc.type Journal Article en
dc.identifier.doi 10.2450/2016.0085-16 en
pubs.begin-page 1 en
dc.rights.holder Copyright: The author en
dc.identifier.pmid 27893353 en
pubs.declined 2016-11-09T17:02:58.248+1300 en
pubs.end-page 10 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype article en
pubs.elements-id 545639 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Medical Sciences en
pubs.org-id Anatomy and Medical Imaging en
pubs.dimensions-id 27893353 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace